2. Search Result
Search Result
Results for "

proliferative diseases

" in MedChemExpress (MCE) Product Catalog:

71

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

3

Peptides

7

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153011
    ROCK-IN-5

    		ROCK ERK GSK-3 Cardiovascular Disease Neurological Disease
    ROCK-IN-5 (compound I-B-37) is a potent inhibitor of ROCK, ERK, GSK, and AGC protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research .
    ROCK-IN-5
  • HY-137122
    3-Pyridine toxoflavin

    		PIN1 Inflammation/Immunology
    3-Pyridine toxoflavin (compound 49) is a PIN1 inhibitor. 3-Pyridine toxoflavin can be used for the research of immune disease proliferative disorder .
    3-Pyridine toxoflavin
  • HY-147579
    Axl-IN-12

    		TAM Receptor Infection Inflammation/Immunology Cancer
    Axl-IN-12 (Example 2) is a potent AXL inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .
    Axl-IN-12
  • HY-147578
    Axl-IN-11

    		TAM Receptor Infection Inflammation/Immunology Cancer
    Axl-IN-11 (Example 1) is a potent AXL inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .
    Axl-IN-11
  • HY-147577
    Axl-IN-10

    		TAM Receptor Inflammation/Immunology Cancer
    Axl-IN-10 (Example 1) is a potent AXL inhibitor, with an IC50 of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .
    Axl-IN-10
  • HY-147576
    Axl-IN-9

    		TAM Receptor Inflammation/Immunology Cancer
    Axl-IN-9 (Example 10) is a potent AXL inhibitor, with an IC50 of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .
    Axl-IN-9
  • HY-147565
    ATR-IN-13

    		ATM/ATR Cancer
    ATR-IN-13 (compound A9) is a potent ATR kinase inhibitor, with an IC50 of 2 nM. ATR-IN-13 can be used for ATR kinase mediated diseases research, such as proliferative diseases and cancer .
    ATR-IN-13
  • HY-151275
    ALK5-IN-28

    		TGF-β Receptor TGF-beta/Smad Cancer
    ALK5-IN-28 (compound Ex-05) is a selective ALK-5 inhibitor (IC50≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit growth of tumour in vivo. ALK5-IN-28 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .
    ALK5-IN-28
  • HY-151281
    ALK5-IN-31

    		TGF-β Receptor Cancer
    ALK5-IN-31 (compound Ex-08) is a selective ALK-5 inhibitor (IC50≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-31 has the potential to inhibit growth of tumour in vivo. ALK5-IN-31 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .
    ALK5-IN-31
  • HY-151282
    ALK5-IN-32

    		TGF-β Receptor TGF-beta/Smad Cancer
    ALK5-IN-32 (compound EX-09) is a selective ALK-5 inhibitor (10 nM<IC50<100 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-32 has the potential to inhibit growth of tumour in vivo. ALK5-IN-32 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .
    ALK5-IN-32
  • HY-142671
    ATR-IN-5

    		ATM/ATR Cancer
    ATR-IN-5 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .
    ATR-IN-5
  • HY-142672
    ATR-IN-6

    		ATM/ATR Cancer
    ATR-IN-6 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .
    ATR-IN-6
  • HY-151289
    ALK5-IN-34

    		TGF-β Receptor TGF-beta/Smad Cancer
    ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC50 value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .
    ALK5-IN-34
  • HY-111424A
    (R)-BDP9066

    		Others Cancer
    (R)-BDP9066 is a potent inhibitor of myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK). (R)-BDP9066 blocks cancer cell invasion. (R)-BDP9066 has the potential for the research of proliferative diseases, such as cancer.
    (R)-BDP9066
  • HY-144867
    CCT245232

    		HSP Cancer
    CCT245232 is a potent inhibitor of heat shock factor 1 (HSF1). HSF1 is the master regulator of the heat shock response, in which multiple genes are induced in response to temperature increase and other stresses. CCT245232 has the potential for the research of proliferative diseases, such as cancer (extracted from patent WO2015049535A1) .
    CCT245232
  • HY-100962A
    AG 99

    Tyrphostin 46; Tyrphostin AG 99

    		 Tyrosinase Cancer
    AG 99 (Tyrphostin 46), a tyrphostin derivative, is a tyrosine kinase inhibitor that increases sister chromatid exchange frequency in transformed CHO-K1 and primary CHE cells. AG 99 is promising for research of proliferative diseases .
    AG 99
  • HY-145026
    ERK1/2 inhibitor 4

    		ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 4
  • HY-145027
    ERK1/2 inhibitor 5

    		ERK Cancer
    ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
    ERK1/2 inhibitor 5
  • HY-145025
    ERK1/2 inhibitor 3

    		ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1) .
    ERK1/2 inhibitor 3
  • HY-145028
    ERK1/2 inhibitor 6

    		ERK Inflammation/Immunology Cancer
    ERK1/2 inhibitor 6 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 6 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021063335A1, compound 1) .
    ERK1/2 inhibitor 6
  • HY-151277
    ALK5-IN-29

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALK5-IN-29 is an selective activin receptor-like kinase (ALK) inhibitor. ALK5-IN-29 can inhibit the activity of ALK5 with an IC50 value of ≤10 nM. ALK5-IN-29 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .
    ALK5-IN-29
  • HY-U00278
    Deloxolone

    (3β,20β)-3-(3-Carboxy-1-oxopropoxy)olean-9(11)-en-29-oic acid

    		 Others Inflammation/Immunology
    Deloxolone has the potential for inflammatory, ischemic and proliferative diseases treatment.
    Deloxolone
  • HY-117810
    JAK2-IN-1

    		JAK Inflammation/Immunology
    JAK2-IN-1 (eExample 2) is a JAK2 inhibitor, and can be used for research of proliferative disease, inflammatory disease, or renal disease .
    JAK2-IN-1
  • HY-147135
    MYF-03-69

    TEAD-IN-3

    		 YAP Cancer
    MYF-03-69 (TEAD-IN-3) is a potent and irreversible TEAD inhibitor. MYF-03-69 disrupts YAP-TEAD association, suppresses TEAD transcriptional activity and inhibits cell growth of Hippo signaling defective malignant pleural mesothelioma (MPM) .
    MYF-03-69
  • HY-148215
    Hsp90-IN-17

    		HSP Cancer
    Hsp90-IN-17 (Example 5) is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17
  • HY-148215A
    Hsp90-IN-17 hydrochloride

    		HSP Cancer
    Hsp90-IN-17 (Example 5) hydrochloride is an HSP90 inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .
    Hsp90-IN-17 hydrochloride
  • HY-15949
    Kif15-IN-2

    		Kinesin Cardiovascular Disease Inflammation/Immunology Cancer
    Kif15-IN-2 is an inhibitor of the mitotic kinesin Kif15, and is used for the research of cellular proliferative diseases.
    Kif15-IN-2
  • HY-153759
    CRX000227

    		PPAR Metabolic Disease
    CRX000227 is a PPAR modulator. CRX000227 can be used for research of metabolic or cell proliferative disorders .
    CRX000227
  • HY-15948
    Kif15-IN-1
    2 Publications Verification

    		 Kinesin Cardiovascular Disease Inflammation/Immunology Cancer
    Kif15-IN-1 is an inhibitor of the mitotic Kinesin family member 15 (Kif15), and is used for the research of cellular proliferative diseases.
    Kif15-IN-1
  • HY-B0328
    Triamcinolone
    2 Publications Verification

    		 Glucocorticoid Receptor Interleukin Related Inflammation/Immunology Endocrinology Cancer
    Triamcinolone is a long-acting corticosteroid with anti-inflammatory, anti-oedematous, anti-proliferative, anti-angiogenetic, immunomodulatory and neuroprotective effects through binding to glucocorticoid receptors. Triamcinolone can relieve several dermatitis, immune diseases and ocular diseases .
    Triamcinolone
  • HY-155094
    DNA polymerase-IN-3

    		DNA/RNA Synthesis Others
    DNA polymerase-IN-3 (Compd 5b) is a coumarin derivative that exhibits inhibitory activity against Taq DNA polymerase and can be used in proliferative disease research .
    DNA polymerase-IN-3
  • HY-143383
    Cdc7-IN-11

    		CDK Cancer
    Cdc7-IN-11 is a highly potent Cdc7 inhibitor with IC50≤1 nM. Cdc7-IN-11 can be used for researching proliferative diseases .
    Cdc7-IN-11
  • HY-143381
    Cdc7-IN-10

    		CDK Cancer
    Cdc7-IN-10 is a highly potent Cdc7 inhibitor with IC50≤1 nM. Cdc7-IN-10 can be used for researching proliferative diseases .
    Cdc7-IN-10
  • HY-112352
    SU9518

    		Others Others
    SU9518 is a tyrosine kinase inhibitor with specific activity against PDGFRα. SU9518 can inhibit the development of proliferative vitreoretinopathy (PVR) in fibroblast and Muller cell rabbit models. SU9518 showed effective inhibitory effects in these models without toxic effects. Therefore, SU9518 has the potential to be used to inhibit PVR in humans and other proliferative eye diseases involving fibrosis and gliosis .
    SU9518
  • HY-12812
    Autotaxin modulator 1

    		Phosphodiesterase (PDE) Neurological Disease Cancer
    Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer .
    Autotaxin modulator 1
  • HY-156553
    BTK-IN-27

    		Btk Inflammation/Immunology Cancer
    BTK-IN-27 (example 8) is a BTK inhibitor (IC50: 0.2 nM). BTK-IN-27 shows anti-proliferative activity in TMD8 cells (IC50: < 5 nM). BTK-IN-27 can be used for research of cancer, lymphoma, leukemia and immunological diseases .
    BTK-IN-27
  • HY-119017
    SB-429201

    		HDAC Cancer
    SB-429201 is a potent and selective HDAC1 (IC50~1.5 μM). SB-429201 displays at least a 20-fold preference for HDAC1 inhibition over HDAC3 and HDAC8 .
    SB-429201
  • HY-151203
    PKG1α activator 3

    		PKG Cardiovascular Disease
    PKG1α activator 3 is a PKG1α activator (EC50 basal/partial=13/0.52 μM). PKG1α activator 3 shows anti-proliferative effects to smooth muscle cell, and can be used in cardiovascular disease research .
    PKG1α activator 3
  • HY-121538
    CUDA

    		Epoxide Hydrolase PPAR Cardiovascular Disease
    CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .
    CUDA
  • HY-13956C
    (R)-Pioglitazone

    (R)-U 72107

    		 PPAR Neurological Disease
    (R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease .
    (R)-Pioglitazone
  • HY-156677
    STC-15

    		METTL3 Cancer
    STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .
    STC-15
  • HY-B0644
    Sucralfate

    Sucrose octasulfate-aluminum complex

    		 Bacterial Infection Inflammation/Immunology Cancer
    Sucralfate (Sucrose octasulfate-aluminum complex) is a potent and orally active gastroprotectant with no systemic effects. Sucralfate inhibits peptic activity and binds to negatively charged subepithelial proteins exposed during mucosal injury, forming a viscous layer that protects the vascular bed and proliferative zone. Sucralfate is used for prevention and research of several gastrointestinal diseases in vivo .
    Sucralfate
  • HY-144044
    EGFR-IN-30

    		EGFR Cancer
    EGFR-IN-30 is a potent EGFR inhibitor with IC50s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research .
    EGFR-IN-30
  • HY-B0617
    S-Adenosyl-L-methionine

    S-Adenosyl methionine; Ademetionine; AdoMet

    		 Endogenous Metabolite Apoptosis Neurological Disease Inflammation/Immunology Cancer
    S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .
    S-Adenosyl-L-methionine
  • HY-160543
    Exatecan-amide-CH2-O-CH2-CH2-OH

    		ADC Cytotoxin Topoisomerase Cancer
    Exatecan-amide-CH2-O-CH2-CH2-OH (Compound 4) is a derivative of Exatecan (HY-13631). Exatecan-amide-CH2-O-CH2-CH2-OH can be used for the research of cell proliferative diseases such as cancer .
    Exatecan-amide-CH2-O-CH2-CH2-OH
  • HY-142677
    PI3K-IN-27

    		PI3K Inflammation/Immunology Cancer
    PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1) .
    PI3K-IN-27
  • HY-114491
    Rineterkib

    		ERK Raf Cancer
    Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib
  • HY-114491A
    Rineterkib hydrochloride

    		ERK Raf Cancer
    Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .
    Rineterkib hydrochloride
  • HY-144732
    TRK/ALK-IN-1

    		Trk Receptor Anaplastic lymphoma kinase (ALK) Cancer
    TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of TRK and ALK. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC50 values of 2.2, 9.3 and 38 nM towards TRKA, ALK WT and ALK L1196M, respectively. TRK/ALK-IN-1 has the potential for the research of cancer diseases .
    TRK/ALK-IN-1
  • HY-118858
    UCPH-102

    		EAAT Neurological Disease Cancer
    UCPH-102 is a highly selective EAAT1 inhibitor with an IC50 of 0.43 µM. UCPH-102 exhibits a specific anti-proliferative effect on T-ALL cells. UCPH-102 also shows good blood-brain permeability, which can be used in studies of amyotrophic lateral sclerosis, Alzheimer’s disease, chronic pain and obsessive compulsive disorder .
    UCPH-102

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: